Microfluidic Device for Pharmacokinetic-Pharmacodynamic Study
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current microfluidic devices for drug development fail to accurately predict drug toxicity and efficacy due to lack of multi-organ interactions and physiologically relevant environments, leading to high drug attrition rates in clinical trials.
Innovation Solution
A microfluidic device with a layered design featuring a base layer, cell culture chamber layer, and fluidic channel layer, where the cell culture chambers are fluidically connected to channels with defined geometries to simulate physiological environments, allowing for pharmacokinetic and pharmacodynamic analysis of drugs and simulating blood flow distribution to organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multi-organ interactions and physiological environments are incorporated into microfluidic devices, then prediction accuracy of drug toxicity and efficacy is improved, but device complexity increases
Solution Approach 1:
The device is divided into multiple independent cell culture chambers (first chamber with hepatocytes, second chamber with tumor cells, third chamber with bone marrow cells) connected by fluidic channels. Each chamber represents a separate organ system, allowing multi-organ interactions to be studied while maintaining modular simplicity in each individual chamber design.
Solution Approach 2:
The patent transitions from traditional 2-D monolayer cell culture to 3-D cell culture by suspending cells in hydrogel beads within the chambers. This dimensional change enables cells to form more physiologically relevant structures while maintaining the compact microfluidic device format.
2Reliability
If 3-D cell culture in hydrogel beads is used, then cell behavior physiological relevance is improved, but manufacturing complexity increases
Solution Approach 1:
The hydrogel beads are formed by self-assembly of cells within the culture medium in the chambers. The cells naturally aggregate and form 3-D structures within the hydrogel matrix without requiring complex external fabrication processes, enabling physiological relevance while maintaining manufacturing simplicity.
3Device complexity
If external pumps are eliminated through defined channel geometries, then device complexity is reduced, but flow rate control precision may worsen
Solution Approach 1:
The patent uses defined geometries of fluidic channels with specific dimensions (width, height, length) to control flow rates passively. By carefully designing the channel parameters during fabrication, physiologically relevant flow rates are achieved without requiring active pump control mechanisms, simplifying the device while maintaining adequate flow precision.
Data Source
AI summary
A microfluidic device for culturing cells, termed a microscale cell culture analog (μCCA), is provided. The microfluidic device allows multiple cell or tissue types to be cultured in a physiologically relevant environment, facilitates high-throughput operation and can be used for drug discovery. The microfluidic device uses gravity-induced fluidic flow, eliminating the need for a pump and preventing formation of air bubbles. Reciprocating motion between a pair of connected reservoirs is used to effect the gravity-induced flow in microfluidic channels. Bacterial contamination is reduced and high throughput enabled by eliminating a pump. The microfluidic device integrates a pharmacokinetic-pharmacodynamic (PK-PD) model to enable PK-PD analyses on-chip. This combined in vitro/in silico system enables prediction of drug toxicity in a more realistic manner than conventional in vitro systems.